Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
140.64
+3.56 (2.60%)
At close: Feb 21, 2025, 4:00 PM
140.60
-0.04 (-0.03%)
After-hours: Feb 21, 2025, 7:30 PM EST
Biogen Revenue
In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%. Biogen had revenue of $2.45B in the quarter ending December 31, 2024, with 2.87% growth.
Revenue (ttm)
$9.68B
Revenue Growth
-1.62%
P/S Ratio
2.12
Revenue / Employee
$1,272,308
Employees
7,605
Market Cap
20.59B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BIIB News
- 3 days ago - Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - Market Watch
- 3 days ago - Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - Business Wire
- 6 days ago - Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma - Seeking Alpha
- 8 days ago - Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts - Benzinga
- 8 days ago - Biogen Analysts Lower Their Forecasts After Q4 Results - Benzinga
- 9 days ago - Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook - Benzinga
- 9 days ago - Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Biogen's stock hit by soft guidance and a decline in sales of MS drugs - Market Watch